Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Application of Realgar-Indigo Naturalis Formula (RIF) for Treatment of Acute Promyelocytic Leukemia (APL)
NCT07503730Phase 3Recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Jun 2025
- Primary completion
- Jun 2028
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Compound Huangdai Tablet in acute promyelocytic leukemia (APL) (2 arms), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Early Death Rate at 30 days. Started Jun 2025; status: recruiting.
02
Drugs
Compound Huangdai Tablet
03
Conditions
acute promyelocytic leukemia (APL)
Beyond the preview
Go deeper on NCT07503730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07503730.